It was observed that in the current HCC TMA dataset, patients with elevated MARCH8 levels and diminished SREBP1 levels had markedly extended OS (Fig. 9F) and RFS rates (Fig. 9G) compared to those with reduced MARCH8 levels and heightened SREBP1 levels. This evidence concerns the gene SREBF1 and hepatocellular carcinoma.